John F. Kennedy's Pain Story: From Autoimmune Disease To Centralized Pain

chronic demyelinating polyneuropathy treatment :: Article Creator

Immunoglobulin Market To Reach $25.6 Billion, Globally, By 2032 At 6.6% CAGR: Allied Market Research

PORTLAND, Ore., Dec. 13, 2023 /PRNewswire/ -- Rise in prevalence of immunodeficiency diseases, increase in adoption of immunoglobulin and growing geriatric population drive the growth of the global immunoglobulin market.

Allied Market Research Logo

Allied Market Research published a report, titled, "Immunoglobulin Market by Application (Primary Immunodeficiency Disease, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura (ITP), Guillain-Barre Syndrome, Others), Mode Of Delivery (Intravenous, Subcutaneous, Intramuscular), and Distribution Channel (Hospital Pharmacy, Drug Stores And Retail Pharmacy, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the global immunoglobulin market was valued at $13.4 billion in 2022 and is projected to reach $25.6 billion by 2032, registering a CAGR of 6.6% from 2023 to 2032.

Request Sample of the Report on Immunoglobulin Market Forecast 2032- https://www.Alliedmarketresearch.Com/request-sample/2586

Prime determinants of growth

Growth in healthcare infrastructure, rise in prevalence of chronic conditions that require immunoglobulin treatment and growth in awareness regarding the use of immunoglobulin are the factors that drive the growth of the global immunoglobulin market. However, higher cost of the treatment hinders market growth. On the contrary, a rise in healthcare expansion is expected to offer remunerative opportunities for the immunoglobulin market during the forecast period.

Report coverage & details:

Report Coverage

Details

Forecast Period

2023–2032

Base Year

2022

Market Size in 2022

$13.4 billion

Market Size in 2032

$25.6 billion

CAGR

6.6 %

No. Of Pages in Report

250

Segments covered

Application, mode of delivery, distribution channel, and region

Drivers

Rise in prevalence of immunodeficiency diseasesIncrease in adoption of immunoglobulinGrowth in geriatric population

Opportunities

Growth in regulatory support

Restraints

Dependence on Plasma SupplyHigh treatment cost

Story continues

Economic Downturn Analysis: Impact of Recession in 2023 on the Immunoglobulin Market

During a recession, the impact on the healthcare industry, including immunoglobulin, can be significant.

Economic downturns may impact healthcare budgets, posing potential constraints on patient access due to financial limitations. Nevertheless, the market can still experience growth driven by essential medical conditions and consistent healthcare demand.

Want to Explore More, Connect to our Analyst- https://www.Alliedmarketresearch.Com/connect-to-analyst/2586

The primary immunodeficiency disease segment to maintain its leadership status throughout the forecast period.

Based on application, the primary immunodeficiency disease segment accounted for the largest share in 2022, accounting for almost more than one-third of the global immunoglobulin market revenue and is expected to register the fastest CAGR of 7.5% during the forecast period. This growth is attributed to several factors, including an increasing prevalence of primary immunodeficiency disorders, heightened awareness leading to early diagnosis, and advancements in immunoglobulin therapies. As these conditions become better understood and diagnostic capabilities improve, there is a rising demand for therapeutic interventions like immunoglobulin treatments.

The intravenous segment to maintain its lead position during the forecast period.

Based on mode of delivery, the intravenous segment dominated the market in 2022, accounting for almost three-fourths of the global immunoglobulin market, this is attributed to the effectiveness and established use of intravenous administration in various therapeutic applications. Intravenous delivery ensures rapid and precise delivery of medications, including immunoglobulins, directly into the bloodstream, enhancing bioavailability and therapeutic outcomes. However, the subcutaneous segment is expected to register highest CAGR of 7.7% during the forecast period owing to several factors including advancements in subcutaneous delivery technologies, increased patient preference for at-home treatments, and the development of more convenient and user-friendly administration methods.

The hospital pharmacy segment to maintain its lead position during the forecast period.

Based on distribution channel, the hospital pharmacy segment accounted for the largest share in 2022, accounting for more than half of the global immunoglobulin market revenue. This is primarily attributed to several factors, including the central role of hospitals in acute and chronic disease management, the availability of comprehensive healthcare services, and the high demand for immunoglobulin therapies in hospital settings. However, the drug stores and retail pharmacy segment is projected to register the highest CAGR of 7.6% during the forecast period. This is primarily due to the expanding role of drug stores and retail pharmacies in providing accessible healthcare services and the increasing trend towards outpatient care. The convenience offered by retail outlets for obtaining immunoglobulin therapies, along with the potential for self-administration and at-home treatments, contributes to the segment's expected accelerated growth.

For Procurement Information- https://www.Alliedmarketresearch.Com/purchase-enquiry/2586

North America will maintain its dominance by 2032

Based on region, North America held the highest market share in terms of revenue in 2022, accounting for more than two-fifths of the global immunoglobulin market revenue owing to the well-established healthcare infrastructure, high prevalence of target diseases necessitating immunoglobulin therapies, and a proactive approach towards advanced medical treatments. However, Asia-Pacific is projected to register the highest CAGR of 7.9% during the forecast period owing to the large population base, increase in healthcare awareness, and rise in incidences of immunodeficiency disorders and autoimmune diseases contributing to a growing demand for immunoglobulin therapies in this region.

Leading Market Players: -

CSL

Kedrion, SpA

Takeda Pharmaceutical Company Limited

Bio Products Laboratory Limited

Prothya Biosolutions

Taibang Biological Group Co., Ltd.

Grifols, S.A.

Octapharma AG

LFB Group

Pfizer Inc.

The report provides a detailed analysis of these key players in the global immunoglobulin market. These players have adopted different strategies such as product launch, collaboration, acquisition, investments and approval to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

Comprehensive Healthcare Industry Research Studies:

Internet of Things in Healthcare Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

Medical Tourism Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

3D Cell Culture Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

Neurovascular Devices Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

Viral Vector and Plasmid DNA Manufacturing Market- Global Opportunity Analysis and Industry Forecast, 2022–2032

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

ContactDavid Correa1209 Orange Street,Corporation Trust Center,Wilmington, New Castle,Delaware 19801 USA.Toll Free: +1-800-792-5285Int'l: +1-503-894-6022UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1-855-550-5975help@alliedmarketresearch.ComWeb: https://www.Alliedmarketresearch.ComFollow Us on: LinkedIn Twitter

Logo - https://mma.Prnewswire.Com/media/636519/Allied_Market_Research_Logo.Jpg

Cision

View original content:https://www.Prnewswire.Com/news-releases/immunoglobulin-market-to-reach-25-6-billion-globally-by-2032-at-6-6-cagr-allied-market-research-302014503.Html

SOURCE Allied Market Research

Expert Defines: Treatment For Chronic Dry Eye

I do like to be very conservative and start with the least invasive first, and so I would say using artificial tears, which are over the counter. It's just a pure lubricating drop. It's not a medicine. It doesn't have any side effects and it's completely safe, so I would like to start with that. And I recommend using it about four times a day to really achieve good therapeutic results.

If the artificial tears are not enough to treat someone's dry eye, the next step would be to go to prescription eye drops, which are designed to help promote the tear gland to produce more tears. There's also something called punctal plugs, which is to keep the tears on the surface longer. Other options, and we're going a more advanced therapy, is to use a special contact lens that will basically create a reservoir so you can have fluid or tears or medications put in the surface of the eye. And the last thing that we could do is use serum tears, so that's actually making special eye drops from your own blood, which contains special nutrients and vitamins, which are very healthy for the surface of the eye.

For dry eye, there's no cure. So there are some people with mild dry eye who can have flare-ups. And so they might be on eye drops for a short period of time and get better and maybe not need it every day. But for the vast majority of people who have chronic dry eye, which is more common as we get older, using or continuing therapy is recommended for the health of the ocular surface, as well as to help with the patient's symptoms. So it would be a continued therapy.

","publisher":"WebMD Video"} ]]>

Hide Video Transcript

[MUSIC PLAYING]

JOANN KANG

HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP To Board Of Directors

WOBURN, Mass., Dec. 11, 2023 /PRNewswire/ -- HanAll Biopharma's partner NurrOn Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related human disorders, is pleased to announce the appointment of Dr. Almira Chabi, MD, EGMP to its Board of Directors, effective November 24, 2023.

Dr. Chabi who is currently Chief Medical Officer and Chief Development Officer at HanAll Pharmaceutical International brings a wealth of experience and expertise to NurrOn's board with a successful track record as a physician-scientist with deep experiences as an executive as well as board member. Dr. Chabi has led programs across multiple therapeutic areas including neurology, immunology, oncology, and ophthalmology as well as applications of artificial intelligence. She is also serving on the Scientific and Medical Research Funding Grants Working Group at the California Institute for Regenerative Medicine.

Dr. Chabi previously held the position of Vice President and Global Therapeutic Area Head for Glaucoma & Neuroprotection as well as Lead for Artificial Intelligence Programs at Santen. Prior to Santen, she worked at Genentech including a senior role on a pivotal Phase III program encompassing over 20 countries. Dr. Chabi began her pharmaceutical career at Merck in the Neuroscience & Ophthalmology Clinical Research Group, working on a range of projects within Ophthalmology as well as Neuroscience leading to multiple successful NDA filings.

In addition to expertise in drug discovery and development, as well as biomarker and device development, she has been extensively involved in due diligences for business development and venture capital teams. Dr. Chabi is also an alumna of Wharton Business School's Executive Management Program and has served as a board representative for multiple companies.

"We are delighted to welcome Dr. Almira Chabi, to our Board of Directors. She possesses a unique blend of skills and insights that will undoubtedly contribute to the strategic direction and success of NurrOn Pharmaceuticals," said Deog Joong Kim, Ph.D, CEO of NurrOn Pharmaceuticals.

Dr. Chabi expressed enthusiasm about joining NurrOn and shared, "I am honored to be a part of NurrOn's Board of Directors. NurrOn is a company that has consistently demonstrated a deep commitment to discovering and developing innovative treatments that have the potential to improve clinical outcomes for Parkinson's patients. I look forward to working collaboratively with the board and the executive team to contribute to the continued growth and success of the organization."

Dr. Chabi joins an esteemed group of professionals on the NurrOn Board, and her appointment aligns with the company's strategic goals for the future.

About NurrOn PharmaceuticalsNurrOn Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related incurable human disorders. Through targeting Nurr1, the master regulator for dopaminergic neuron development and maintenance, we aim to develop a paradigm changing PD treatment to improve patients' quality of life. While currently there are only symptomatic treatment options for patients with PD, there have not been any successful therapies to slow or prevent the progression of the disease. We believe that disease-modifying therapies will be achieved through targeting Nurr1, which has generated supportive data as a new druggable PD target. NurrOn was awarded a substantial grant from Michael J. Fox Foundation in support of the Phase 1 clinical trial of ATH-399A/HL192, that initiated in the second half of 2023. For further information on NurrOn Pharmaceuticals, please visit our official website or contact info@nurronpharma.Com.

About HanAll BiopharmaHanAll Biopharma (KRX: 009420.KS) is a global biopharmaceutical company with presence in Korea, the USA, Japan, and Indonesia with a mission of making meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products for 50 years.

HanAll has also expanded its focus in recent years to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. Its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials across the world for the treatment of autoimmune diseases including generalized myasthenia gravis (gMG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves' disease (GD). Another main asset, HL036 (INN: tanfanercept), a TNF-alpha inhibitor protein, is under development in Phase 3 clinical studies in the US for the treatment of dry eye disease. For further information, visit our website and connect with us on LinkedIn. For any media inquiries, please contact HanAll PR/IR (pr@hanall.Com, ir@hanall.Com).

View original content to download multimedia:https://www.Prnewswire.Com/news-releases/hanall-biopharmas-partner-nurron-pharmaceuticals-incorporated-appoints-dr-almira-chabi-md-egmp-to-board-of-directors-302010850.Html